POSTERS ASCO 2024

Cáncer de mama

Local, regional y adyuvante

Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.

Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.

Abstract: 1101 Poster Bd #: 79

Poster

Descargar

Autor
Antonio Llombart-Cussac, MD

Hospital Arnau de Vilanova, Valencia, Spain

Compartir:

Una iniciativa científica de:

eco clover

Con el patrocinio de:

REGENERON